# Increased Risk of Esophageal Eosinophilia and Eosinophilic **Esophagitis in Patients With Active Celiac Disease on Biopsy**

Elizabeth T. Jensen,\*,<sup>‡,a</sup> Swathi Eluri,<sup>‡,a</sup> Benjamin Lebwohl,<sup>§,||</sup> Robert M. Genta,<sup>¶,#,b</sup> and Evan S. Dellon\*,<sup>‡,b</sup>

\*Center for Esophageal Diseases and Swallowing and <sup>‡</sup>Center for Gastrointestinal Biology and Disease. Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; <sup>§</sup>Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York; <sup>11</sup>Miraca Research Institute, Miraca Life Sciences, Irving, Texas; and <sup>#</sup>Dallas Veterans Affairs Medical Center and University of Texas Southwestern Medical Center, Dallas, Texas

BACKGROUND & AIMS:	The possible association between eosinophilic esophagitis (EoE) and celiac disease is contro- versial because prior results have been contradictory. We aimed to determine the relationship between EoE and celiac disease among patients with concomitant esophageal and duodenal biopsies.
METHODS:	We conducted a cross-sectional study in a U.S. national pathology database by using data from January 2009 through June 2012. Our primary case definition was defined by the presence of esophageal eosinophilia with ≥15 eosinophils per high-power field. The crude and adjusted (for age and sex) odds of esophageal eosinophilia for patients with active celiac disease were compared with those without celiac disease. Sensitivity analyses were performed by using more stringent case definitions and by estimating the associations between celiac disease and reflux esophagitis and celiac disease and Barrett's esophagus.
RESULTS:	Of 292,621 patients in the source population, 88,517 with both esophageal and duodenal bi- opsies were studied. Four thousand one hundred one (4.6%) met criteria for EoE, and 1203 (1.4%) met criteria for celiac disease. Odds of EoE were 26% higher in patients with celiac disease than in patients without celiac disease (adjusted odds ratio [aOR], 1.26; 95% confidence interval [CI], 0.98–1.60). The magnitude of association varied according to EoE case definition, but all definitions showed a weak positive association between the 2 conditions. There was no association between celiac disease and reflux esophagitis (aOR, 0.95; 95% CI, 0.85–1.07) or Barrett's esophagus (aOR, 0.89; 95% CI, 0.69–1.14) and celiac disease.
CONCLUSIONS:	There is a weak increase in EoE in patients with celiac disease. This association strengthened with increasingly stringent definitions of EoE and was not observed for other esophageal conditions. In patients with celiac disease, concomitant EoE should be considered in the correct clinical setting.

Keywords: Eosinophilic Esophagitis; Celiac Disease; Epidemiology; Prevalence; Pathology.

E osinophilic esophagitis (EoE) is a chronic immune and antigen-mediated disease characterized by clinical symptoms of esophageal dysfunction and eosinophilic infiltration of  $\geq$ 15 eosinophils per high-power field (eos/hpf) in the absence of other contributing causes of eosinophilia.<sup>1,2</sup> EoE affects both adults and children at a prevalence of 50-100/100,000 and has been increasing in incidence at a rate of 10/100,000 per year.<sup>3–5</sup> Atopic conditions such as asthma and allergic rhinitis are strongly associated with EoE<sup>6</sup> and both aeroallergens and food antigens contribute to the pathogenesis.<sup>7-9</sup> As a result, there has been a focus on the utility of food

elimination diets in achieving clinicopathologic improvement,<sup>10–13</sup> and milk and wheat have been identified as common triggers of disease.<sup>13,14</sup>

<sup>a</sup>Authors share co-first authorship; <sup>b</sup>Authors share co-last authorship.

© 2015 by the AGA Institute 1542-3565/\$36.00 http://dx.doi.org/10.1016/j.cgh.2015.02.018

Abbreviations usedin this paper: aOR, adjusted odds ratio; CI, confidence interval; EGD, esophagogastroduodenoscopy; EoE, eosinophilic esophagitis; eos/hpf, eosinophils per high-power field; PPI, proton pump inhibitor; SIR, standardized incidence ratio.

### 2 Jensen et al

#### Clinical Gastroenterology and Hepatology Vol. ■, No. ■

Similar to EoE, celiac disease is an immune-mediated condition. Celiac disease is triggered by gluten in genetically predisposed individuals,<sup>15,16</sup> and because wheat can also trigger EoE, several studies have investigated the relation between the 2 diseases.<sup>17–20</sup> However, the results are conflicting. One study reported that the prevalence of EoE in celiac disease was 9 times higher than in the general population.<sup>17</sup> Other studies have reported prevalence of EoE in patients with celiac disease ranging between 1.2% and 4.4%,<sup>19–22</sup> and one investigation indicated no association between the 2 conditions.<sup>23</sup> It is possible that selection bias or a lack of a suitable comparator group may explain the contradictory findings of these previously conducted studies, and additional investigation into the relationship between EoE and celiac disease is warranted.

The primary aim of the study was to determine the relationship between EoE and celiac disease among patients with concomitant esophageal and duodenal biopsies by using a large pathology database. We hypothesized that there would be no significant relationship between these conditions and that the previously reported associations may be attributable to selection bias.

# Methods

# Study Design and Data Source

This was a cross-sectional study of all patients with esophageal and duodenal biopsy specimens in a U.S national pathology database who were examined between January 1, 2009 and June 30, 2012 by pathologists at Miraca Life Sciences. Miraca Life Sciences is a specialized pathology laboratory serving outpatient endoscopy centers throughout the United States. They review samples from 43 states, Washington, DC, and Puerto Rico, with central specimen processing in 1 of 3 laboratories (Irving, TX, Phoenix, AZ, and Boston, MA). Each laboratory follows identical sectioning and staining procedures. An experienced group of 41 subspecialty trained gastrointestinal pathologists review the slides. All biopsy reports are deposited into a central database, which also includes information about patient age, sex, and indication for esophagogastroduodenoscopy (EGD). Uniformity among pathologists is maximized through a standardized approach to specimen handling and a predetermined set of diagnostic criteria and terminology for biopsy reading. Consensus is maintained and updated through an extensive quality assurance process that includes 1%-2% random review of cases. Details about this methodology have been previously published.<sup>24–26</sup> The study was approved by both the University of North Carolina and the Miraca Life Sciences institutional review boards.

# Study Population

A de-identified database of unique patients with esophageal and duodenal biopsy specimens was generated for this study. We initially started with 320,319 patients who had esophageal biopsies, of whom 90,994 also had concomitant duodenal biopsies. We then excluded those who had a clinical history of EoE or celiac disease but no corresponding histologic evidence of active disease at the time of biopsy, because we could not confirm their case status. In addition, we also excluded subjects with duodenal intraepithelial lymphocytosis but without other features of celiac disease.

Proton pump inhibitor (PPI) use before endoscopy was unknown in this dataset. Therefore, we were unable to assess for or exclude PPI-responsive esophageal eosinophilia. In our primary analysis, patients were defined as having esophageal eosinophilia if there were  $\geq 15 \text{ eos/hpf}$ (×400 magnification; area per hpf = 0.237 mm<sup>2</sup>). In sensitivity analysis, the severity of eosinophilia was evaluated in further detail by categorizing the density in ranges of eos/hpf (empirically defined as  $\geq 50$  or  $\geq 100$  eos/hpf) and documenting the presence of eosinophilic microabscesses (defined as clusters of  $\geq 4$  contiguous eosinophils).<sup>27</sup> These patients were then further categorized into EoE case definitions by creating several increasingly stringent, proxy definitions for EoE that were based on the presence of factors consistent with EoE diagnosis.

Cases of celiac disease were defined by duodenal biopsies with a Marsh score of 3. Pathologic findings for these lesions included villous atrophy (3a, partial; 3b, subtotal villous atrophy, 3c, total villous atrophy or flat mucosa), with concurrent increase in the ratio of intraepithelial lymphocytes to enterocytes, with >40 intraepithelial lymphocytes/100 enterocytes.<sup>28,29</sup> Although less advanced Marsh scores can represent subtler histologic forms of celiac disease, because of the lower specificity of these lesions for celiac disease, only Marsh class 3 was included in our case definition, as has been described previously in this dataset.<sup>30–32</sup>

Clinical characteristics of patients were identified on the basis of upper gastrointestinal symptoms or conditions that were noted as the indication for endoscopy (ie, suspected EoE, dysphagia symptoms, reflux symptoms, or gastroesophageal reflux disease [defined as a report of heartburn, regurgitation, or reflux], suspected celiac disease, nausea and/or vomiting, weight loss or failure to thrive, diarrhea, abdominal pain or dyspepsia, chest pain, and screening or follow-up of a known diagnosis of Barrett's esophagus). We also recorded the presence of other conditions noted on histologic examination such as reflux esophagitis (defined as a mixed active/chronic inflammatory pattern with squamous papillomatosis and basal hyperplasia), intestinal metaplasia (Barrett's esophagus), eosinophilic gastroenteritis, and any known history of inflammatory bowel disease for use in sensitivity analyses.

# Statistical Analysis

**Primary analysis.** We described the distribution of demographic characteristics for the overall study

population, those with esophageal eosinophilia, and those with celiac disease. We then used generalized linear models to estimate whether, among those with both esophageal and duodenal biopsies, there was an increased odds of concomitant esophageal eosinophilia in patients meeting diagnostic criteria for celiac disease relative to those without the diagnosis of celiac disease. Crude and adjusted analyses (adjusted for age and sex) were performed. We evaluated whether there was an interaction with age or effect modification by age. We also produced stratum-specific estimates for adult (age >18 years) and pediatric subgroups.

Sensitivity analyses. We performed several a priori sensitivity analyses. First, we examined the association between celiac disease and increasing levels of esophageal eosinophilia on biopsy (nested categories of  $\geq 15$ ,  $\geq 50$ , and >100 eos/hpf). A second analysis was performed to examine the association between celiac disease and our EoE case definitions, which incorporated additional information on histopathology observations and clinical indication for endoscopy. We selected increasingly stringent and specific definitions<sup>24-26</sup> including >15 eos/hpf and documentation of dysphagia,  $\geq$ 15 eos/hpf, dysphagia, exclusion of patients with clinical or histologic data suggesting alternative explanations for the eosinophilia (reflux/heartburn symptoms, reflux esophagitis, Barrett's esophageal on biopsy, inflammatory bowel disease, and eosinophilic gastroenteritis), and the presence of eosinophilic microabscesses in the esophageal epithelium.

The final sensitivity analysis performed was to examine any association between celiac disease and other esophageal disorders such as Barrett's esophagus and reflux esophagitis. Because our study population was restricted to those patients with esophageal and duodenal biopsies, we wanted to determine whether any relationship between EoE and celiac disease was confounded by underlying factors that predisposed this group to having biopsies obtained from both locations. If this was the case, then we hypothesized that we would see an association between celiac disease and Barrett's esophagus or reflux esophagitis.

## Results

#### Patient Characteristics

We identified 88,517 patients who had both esophageal and duodenal biopsies and who also met the inclusion criteria. The mean age in the group was 51.1 years, with 38.2% male (Table 1). The most common indication for upper endoscopy was abdominal pain/dyspepsia (52.1%), followed by heartburn (43.4%), dysphagia/ odynophagia (16.5%), and diarrhea (13.4%). The mean of the maximum eosinophil count was 2.9 eos/hpf, and 1.1% had microabscesses.

There were 4101 patients (4.6%) who met criteria for esophageal eosinophilia defined as  $\geq$ 15 eos/hpf. The

 
 Table 1. Demographic Characteristics, Clinical Symptoms, and Histologic Features of Study Population

	-	•
	Study population (n = 88,517)	Esophageal eosinophilia <sup>a</sup> (n = 4101)
Demographic characteristic		
Age (y), mean $\pm$ standard	51.1 ± 18.2	39.6 + 17.6
deviation		
Male, n (%)	33,786 (38.2)	2347 (57.2)
Clinical symptoms/EGD		
indications, <sup>b</sup> n (%)		
Dysphagia/odynophagia	14,558 (16.5)	1510 (36.8)
Heartburn	38,470 (43.4)	1562 (38.1)
Chest pain	3091 (3.5)	126 (3.1)
Abdominal pain/dyspepsia	46,132 (52.1)	1843 (44.9)
Nausea/vomiting	10,826 (12.2)	474 (11.6)
Weight loss	5059 (5.7)	145 (3.5)
Diarrhea	11,864 (13.4)	533 (13.0)
Histologic features		
Maximum eosinophil	$2.9 \pm 11.9^{\circ}$	$\textbf{36.6} \pm \textbf{23.9}$
count, mean $\pm$		
standard deviation		
Eosinophil	929 (1.1)	929 (22.7)
microabscesses, n (%)		

<sup>a</sup>Patients with esophageal eosinophilia on esophageal biopsy with minimum count  $\geq$ 15 eos/hpf and with EoE pathology code.

<sup>b</sup>Multiple indications could be listed for each procedure.

<sup>c</sup>Includes 52,393 patients with normal or documented number of esophageal eosinophils on biopsy.

mean age was lower at 39.6 years, with higher percentage of male patients (57.2%) compared with the study population (Table 1). In this group, 36.8% had dysphagia, and the mean eosinophil count was 36.6 eos/ hpf, with 22.7% having eosinophil microabscesses.

A total of 1203 patients (1.4%) met criteria for celiac disease. There was no major difference in age between those with and without celiac disease (49.6 vs 51.1 years), and the groups had similar sex distributions (Table 2). Common symptoms and endoscopy indications in the celiac disease group were abdominal pain/dyspepsia (38.9%), heartburn (35.7%), and diarrhea (15.9%).

# Relationship Between Esophageal Eosinophilia, Eosinophilic Esophagitis, and Celiac Disease

There were 72 subjects with celiac disease who had concomitant esophageal eosinophilia with  $\geq$ 15 eos/hpf (6.0%) compared with 4029 in the non-celiac group (5.6%). This corresponds to 26% higher odds of esophageal eosinophilia, adjusted for age and sex, among patients with celiac disease when compared with patients without celiac disease (adjusted odds ratio [aOR], 1.26; 95% confidence interval [CI], 0.98–1.60) (Table 3). We found no statistically significant evidence of interaction with age (P = .20 for interaction term). However, stratum-specific estimates were suggestive of an association between

Table 2. Demographic Characteristics, Clinical Symptoms,		
Histologic Features, and Presence of Reflux		
Esophagitis or Barrett's Esophagus by Celiac		
Disease Status <sup>a</sup>		

	Celiac dis		
	Yes (n = 1203)	No (n = 87,314)	P value <sup>a</sup>
Demographic characteristic			
Age (y), mean $\pm$ standard deviation	$49.6\pm18.7$	51.1 ± 18.2	<.01
Male, n (%)	471 (39.2)	33,315 (38.2)	.48
Clinical symptoms/EGD indications, n (%)			
Dysphagia/odynophagia	186 (15.5)	14,372 (16.5)	.35
Heartburn	429 (35.7)	38,041 (43.6)	<.01
Chest pain	30 (2.5)	3061 (3.5)	.06
Abdominal pain/dyspepsia	468 (38.9)	45,664 (52.3)	<.01
Nausea/vomiting	123 (10.2)	10,703 (12.3)	.03
Weight loss	75 (6.2)	4984 (5.7)	.43
Diarrhea	191 (15.9)	11,673 (13.4)	.01
Histologic features			
Maximum eosinophil count, mean $\pm$ standard deviation	3.9 (13.9) <sup>°</sup>	2.9 ± 11.8 <sup>d</sup>	.02
Eosinophil microabscesses, n (%)	18 (1.5)	911 (1.0)	.13
$\geq$ 15 eos/hpf, n (%)	72 (6.0)	4029 (5.6)	.02
Reflux esophagitis, n (%)	446 (37.1)	33,418 (38.3)	.40
Barrett's esophagus, n (%)	69 (5.7)	5773 (6.6)	.22

<sup>a</sup>*P* values for significant difference in distribution of proportions and *P* value for difference in mean age and eosinophil count.

<sup>b</sup>Characterized by severe/diffuse villous blunting with intraepithelial lymphocytosis.

<sup>c</sup>Includes 712 patients with documented number of esophageal eosinophils on biopsy.

<sup>d</sup>Includes 51,681 patients with documented number of esophageal eosinophils on biopsy.

esophageal eosinophilia and celiac disease in adults (age  $\geq$ 18 years) (aOR, 1.35; 95% CI, 1.04–1.73) but not in children (aOR, 0.94; 95% CI, 0.42–2.07).

On sensitivity analysis, the magnitude of the association varied according to EoE case definition (Table 3),

#### Clinical Gastroenterology and Hepatology Vol. ■, No. ■

but all definitions were suggestive of a weak positive association. For example, the odds when defining EoE as  $\geq$ 50 eos/hpf were 58% higher for those patients with concomitant celiac disease (aOR, 1.58; 95% CI, 1.04–2.41). In contrast to these findings, there was no association between celiac disease and either reflux esophagitis (aOR, 0.95; 95% CI, 0.85–1.07) or Barrett's esophagus (aOR, 0.89; 95% CI, 0.69–1.14).

# Discussion

Multiple and varied food antigens have been implicated in the pathogenesis of EoE, similar to the role gluten plays in celiac disease. On the basis of this, there is a question of whether the 2 conditions are associated. In the present study, which examined subjects with paired esophageal and duodenal biopsies in a large pathology database, we found that the odds of esophageal eosinophilia and our constructed case definitions of EoE were mildly increased in patients with celiac disease compared with those without celiac disease. This association generally became stronger when more stringent definitions of EoE were applied. There was no association between celiac disease and either reflux esophagitis or Barrett's esophagus, indicating that the association between esophageal eosinophilia and celiac disease could not likely be explained by selection bias.

Previous literature on the relationship between EoE and celiac disease has been conflicting. Most of these studies were conducted in the pediatric population, and prevalence of EoE in pediatric celiac disease patients has ranged from 3.2% to 4.4%.<sup>19–21</sup> However, examining prevalence of EoE among celiac disease without a comparator group that has undergone upper endoscopy may lead to erroneous assumptions about the increased prevalence of EoE in this group. For example, one study estimated 6.5% of patients undergoing upper endoscopy for any reason would have EoE.<sup>33</sup> Another pediatric study found 6 cases of celiac disease out of the 17 cases with EoE in children referred for upper endoscopy in Italy.<sup>18</sup> When

EoE definition	n	EoE with celiac disease on biopsy (n)	OR (95% CI)	aOR <sup>a</sup> (95% CI)
No EoE	84,416	1131	Referent	Referent
EoE as defined by				
$\geq$ 15 eos/hpf	4101	72	1.32 (1.04–1.67)	1.26 (0.98-1.60)
$\geq$ 15 eos/hpf and dysphagia	1406	23	1.23 (0.81–1.86)	1.18 (0.78–1.80)
≥15 eos/hpf, eosinophilic microabscesses, and exclusion of competing conditions <sup>b</sup>	230	4	1.30 (0.49–3.51)	1.25 (0.46–3.37)
$\geq$ 50 eos/hpf	1050	23	1.65 (1.09–2.50)	1.58 (1.04–2.41)
≥100 eos/hpf	227	5	1.66 (0.68–4.03)	1.57 (0.64–3.82)

Table 3. Association Between Esophageal Eosinophilia and Celiac Disease With Increasingly Restrictive Definitions of EoE

<sup>a</sup>Adjusted for age, sex.

<sup>b</sup>Competing conditions included reflux/heartburn symptoms, reflux esophagitis, Barrett's esophagus, inflammatory bowel disease, and eosinophilic gastroenteritis.

## **2015**

treated with a gluten-free diet, the children had both symptomatic and histologic improvement of EoE, suggesting a possible shared pathogenic trigger between the 2 diseases. On the contrary, there was no histologic improvement in another small cohort of pediatric patients treated with a gluten-free diet.<sup>21</sup> A retrospective, population-based review from 2004 to 2008 of both adults and children found an association between EoE and celiac disease only in children (defined as <19 years of age).<sup>22</sup> Here the standardized incidence ratio (SIR) for EoE within the pediatric celiac disease cohort was 48.4 (95% CI, 9.73–141.41), and the SIR for celiac disease in the EoE cohort was 75.1 (95% CI, 15.08-219.28). A study by Thompson et al<sup>34</sup> of 666 patients of all ages with celiac disease identified EoE in 14 patients and an overall ageand sex-adjusted SIR of 16. In contrast, no association between EoE and celiac disease was found in a population-based cohort of randomly selected adults undergoing upper endoscopy.<sup>24</sup> Similarly, a study by Lucendo et al<sup>35</sup> did not find increased HLA DO2 and DO8 (implicated in patients with celiac disease) in subjects with EoE when compared with controls. Thus, the literature on this topic has been contradictory and confusing, likely because of variable study designs, inclusion criteria, and comparator groups, as well as relatively small sample sizes. It is not surprising that a recent systematic review examining the association between EoE and celiac disease found no clear association between the 2 conditions and concluded that there was a lack of robust studies for summarizing the relationship.<sup>36</sup>

Therefore, there are a number of strengths to our study. To our knowledge, this is the largest investigation of the association between EoE and celiac disease. In restricting our study population to those patients with both esophageal and duodenal biopsies, we addressed the potential selection bias introduced in previously conducted studies. Nevertheless, aside from pediatric gastroenterology practices where biopsies of the esophagus, stomach, and duodenum are routinely obtained, there would typically need to be a rationale, either clinically or endoscopically, for an adult patient to have both esophageal and duodenal biopsies obtained. In using a comparator group of patents with both esophageal and duodenal biopsies, any observed association could be confounded by factors contributing to the need for biopsies from both locations. However, by restricting the sample to those with endoscopy and biopsies, we removed the possible confounding effect of endoscopy (with duodenal and esophageal biopsies) on the observed association. The potential that the association between the 2 different diseases represents an artifact of confounding bias has been previously discussed.<sup>37</sup> We adjusted on age and sex, both possible confounders in the association between celiac disease and EoE, but other unmeasured factors that we could not account for may have also contributed. If this were the case, we would hypothesize that celiac disease would also be associated with other esophageal conditions. However, we found no

increase in odds of either Barrett's esophagus or reflux esophagitis in patients with celiac disease. These null results lend credence to the idea that the association between EoE and celiac disease is not spurious. Finally, the a priori sensitivity analyses, where more restrictive case definitions of EoE were applied, generally showed a stronger relation with celiac disease.

There are also limitations to consider with the design of this current study. First, the retrospective design limits the amount of data available. In addition, because the study is cross-sectional, we are only able to comment on the association between the 2 diseases and not on causality. Third, clinical information was limited to the data provided on the endoscopy report and pathology requisition. Therefore, the diagnosis of esophageal eosinophilia and celiac disease was primarily based on established histopathologic features, and description of clinical features of patients may be incomplete. Because we do not have full data about endoscopic findings, we also cannot comment on the specific indications for esophageal biopsy. Also, there were no data on PPI use before endoscopy; thus, we could not preclude the possibility that some cases could represent patients with PPI-responsive esophageal eosinophilia.

In summary, this large, retrospective, cross-sectional study found that the odds of esophageal eosinophilia were 26% higher among patients with celiac disease as compared with patients without celiac disease, and that the odds tended to increase with more stringent EoE case definitions. This weak but persistent association builds on the discrepant results previously reported in the literature in smaller studies and offers reduced potential for selection bias with the use of comparison groups. Although this association is not strong enough to recommend obtaining esophageal biopsies in all celiac disease patients to assess for EoE, certain esophageal symptoms, such as dysphagia, chest discomfort, or heartburn, in a patient with celiac disease should raise the question of EoE as a possible cause. In patients identified to have both EoE and celiac disease, mechanistic studies are required to determine whether the 2 conditions truly share a similar pathogenesis.

#### References

- Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128:3–20.e6; quiz 1–2.
- Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol 2013;108:679–692; quiz 93.
- Kapel RC, Miller JK, Torres C, et al. Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups. Gastroenterology 2008;134:1316–1321.
- Dellon ES. Epidemiology of eosinophilic esophagitis. Gastroenterol Clin North Am 2014;43:201–218.
- Dellon ES, Jensen ET, Martin CF, et al. Prevalence of eosinophilic esophagitis in the United States. Clin Gastroenterol Hepatol 2014;12:589–596.

# **ARTICLE IN PRESS**

### 6 Jensen et al

#### Clinical Gastroenterology and Hepatology Vol. ■, No. ■

- Okada H, Kuhn C, Feillet H, et al. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol 2010;160:1–9.
- Moawad FJ, Veerappan GR, Lake JM, et al. Correlation between eosinophilic oesophagitis and aeroallergens. Aliment Pharmacol Ther 2010;31:509–515.
- 8. Fogg MI, Ruchelli E, Spergel JM. Pollen and eosinophilic esophagitis. J Allergy Clin Immunol 2003;112:796–797.
- 9. Aceves SS. Food allergy testing in eosinophilic esophagitis: what the gastroenterologist needs to know. Clin Gastroenterol Hepatol 2014;12:1216–1223.
- Spergel JM, Andrews T, Brown-Whitehorn TF, et al. Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol 2005;95:336–343.
- 11. Wolf WA, Jerath MR, Sperry SL, et al. Dietary elimination therapy is an effective option for adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2014;12:1272–1279.
- Henderson CJ, Abonia JP, King EC, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2012;129:1570–1578.
- Gonsalves N, Yang GY, Doerfler B, et al. Elimination diet effectively treats eosinophilic esophagitis in adults: food reintroduction identifies causative factors. Gastroenterology 2012; 142:1451–1459; quiz e14–e15.
- Lucendo AJ, Arias A, Gonzalez-Cervera J, et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol 2013; 131:797–804.
- Fasano A. Clinical presentation of celiac disease in the pediatric population. Gastroenterology 2005;128(Suppl 1):S68–S73.
- Pellicano R, De Angelis C, Ribaldone DG, et al. 2013 update on celiac disease and eosinophilic esophagitis. Nutrients 2013; 5:3329–3336.
- Verzegnassi F, Bua J, De Angelis P, et al. Eosinophilic oesophagitis and coeliac disease: is it just a casual association? Gut 2007;56:1029–1030.
- Quaglietta L, Coccorullo P, Miele E, et al. Eosinophilic oesophagitis and coeliac disease: is there an association? Aliment Pharmacol Ther 2007;26:487–493.
- Leslie C, Mews C, Charles A, et al. Celiac disease and eosinophilic esophagitis: a true association. J Pediatr Gastroenterol Nutr 2010;50:397–399.
- Ooi CY, Day AS, Jackson R, et al. Eosinophilic esophagitis in children with celiac disease. J Gastroenterol Hepatol 2008;23(Pt 1):1144–1148.
- Abraham JR, Persad R, Turner JM, et al. Gluten-free diet does not appear to induce endoscopic remission of eosinophilic esophagitis in children with coexistent celiac disease. Can J Gastroenterol 2012;26:521–524.
- Stewart MJ, Shaffer E, Urbanski SJ, et al. The association between celiac disease and eosinophilic esophagitis in children and adults. BMC Gastroenterol 2013;13:96.
- Ludvigsson JF, Aro P, Walker MM, et al. Celiac disease, eosinophilic esophagitis and gastroesophageal reflux disease, an adult population-based study. Scand J Gastroenterol 2013; 48:808–814.

- Hurrell JM, Genta RM, Dellon ES. Prevalence of esophageal eosinophilia varies by climate zone in the United States. Am J Gastroenterol 2012;107:698–706.
- Jensen ET, Hoffman K, Shaheen NJ, et al. Esophageal eosinophilia is increased in rural areas with low population density: results from a national pathology database. Am J Gastroenterol 2014;109:668–675.
- Dellon ES, Peery AF, Shaheen NJ, et al. Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. Gastroenterology 2011; 141:1586–1592.
- Collins MH. Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases. Gastroenterol Clin North Am 2014;43:257–268.
- Oberhuber G. Histopathology of celiac disease. Biomed Pharmacother 2000;54:368–372.
- Marsh MN. Gluten, major histocompatibility complex, and the small intestine: a molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992;102:330–354.
- Carmack SW, Genta RM. The diagnostic value of the duodenal biopsy: a clinico-pathologic analysis of 28,000 patients. Dig Liver Dis 2010;42:485–489.
- Lebwohl B, Blaser MJ, Ludvigsson JF, et al. Decreased risk of celiac disease in patients with Helicobacter pylori colonization. Am J Epidemiol 2013;178:1721–1730.
- Lebwohl B, Kapel RC, Neugut AI, et al. Adherence to biopsy guidelines increases celiac disease diagnosis. Gastrointest Endosc 2011;74:103–109.
- Veerappan GR, Perry JL, Duncan TJ, et al. Prevalence of eosinophilic esophagitis in an adult population undergoing upper endoscopy: a prospective study. Clin Gastroenterol Hepatol 2009;7:420–426.
- Thompson JS, Lebwohl B, Reilly NR, et al. Increased incidence of eosinophilic esophagitis in children and adults with celiac disease. J Clin Gastroenterol 2012;46:e6–e11.
- **35.** Lucendo AJ, Arias A, Perez-Martinez I, et al. Adult patients with eosinophilic esophagitis do not show an increased frequency of the HLA-DQ2/DQ8 genotypes predisposing to celiac disease. Dig Dis Sci 2011;56:1107–1111.
- Lucendo AJ, Arias A, Tenias JM. Systematic review: the association between eosinophilic oesophagitis and coeliac disease. Aliment Pharmacol Ther 2014;40:422–434.
- Allen KJ, Heine RG. Eosinophilic esophagitis: trials and tribulations. J Clin Gastroenterol 2011;45:574–582.

#### Reprint requests

Address requests for reprints to: Evan S. Dellon, MD, MPH, CB#7080, Bioinformatics Building, 130 Mason Farm Road, UNC-CH, Chapel Hill, North Carolina 27599-7080. e-mail: edellon@med.unc.edu; fax: (919) 843-2508.

#### **Conflicts of interest**

These authors disclose the following: Benjamin Lebwohl has received research funding from Alvine. Robert Genta is an employee of Miraca Life Sciences. Evan Dellon has received research funding from Meritage Pharma, is a consultant for Aptalis, Novartis, Receptos, and Regeneron, and has received an educational grant from Diagnovus. The remaining authors disclose no conflicts.

#### Funding

Supported in part by National Institutes of Health Award K23 DK090073 (E.S.D.).